Pipeline Insight: Acute Stroke

Full Title: Pipeline Insight: Acute Stroke: Commercial risk offsets high unmet need

Introduction

Stroke is one of the top three causes of death and its incidence in the seven major markets is expected to increase in the next ten years because of an aging population. Long term disability caused by stroke is a major economic burden on healthcare systems, current treatment options are limited and general awareness of stroke is poor.

Scope

• Analysis of patient potential, unmet needs and clinical trial design in acute stroke
• Overview of drugs in late- and early-stage clinical development; with analysis of key companies involved in the R&D pipeline
• Detailed profiles of key compounds in development for use in acute stroke, with forecasts of drug revenues to 2017
• Review of the recent failures in acute stroke (NXY-059 and NovoSeven)

Highlights

In the setting of acute stroke, a patient’s treatment options and recovery prospects are a function of time. Therefore any delay related to the time-to-treatment constitutes a resistor to market entry and uptake for stroke therapies in the acute care hospital setting. The R&D landscape is shaped by the need to minimize the commercial risk associated with developing drugs for the acute-care stroke market - the majority of the companies contribute only one candidate drug to the acute stroke pipeline. The future prognosis for the acute stroke therapy is marred by the long list of failures, especially of neuroprotectants. Thrombolytics are also plagued by shortcomings in trial design, which result either in discontinuation of the drugs, or prolonged development that leads in its turn to the low credibility of the compounds.

Reasons to Purchase

• Understand clinical and environmental unmet needs in the acute stroke market based on key opinion leader comments
• Benchmark key late-stage pipeline products against the current market leader and class comparator
• Assess the 7 major markets (US, Japan, 5 major EU) sales forecasts of late-stage pipeline drugs and examine their clinical and commercial potential.

Pages: 295

Table of Contents

Download TOC in PDF